menu
    • menu

    Company profile for Scynexis

    NEW Drugs in Dev: 8
    FAMAR CDMO- From early development to commercial manufacturing.

    Virtual Booth

    Contact Supplier

    Rochem, your partner in developing, sourcing, and supplying pharmaceutical & animal health ingredients of Chinese origin.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-01-12

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    Together we can improve the quality of life

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    REF. STANDARDS & IMPURITIES

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    We are committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by developing innovative therapies. We believe that our lead compound, Ibrexafungerp (formerly SCY-078), has the potential to be an essential therapy in the treatment of multiple serious fungal infections, including vulvovaginal candidiasis, invasive candidiasis, invasive aspergillosis and refr...
    We are committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by developing innovative therapies. We believe that our lead compound, Ibrexafungerp (formerly SCY-078), has the potential to be an essential therapy in the treatment of multiple serious fungal infections, including vulvovaginal candidiasis, invasive candidiasis, invasive aspergillosis and refractory invasive fungal infections.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    ScynexisUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    1 Evertrust Plaza 13th Floor Jersey City, NJ 07302
    Telephone
    Telephone
    (201) 884-5485
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.scynexis.com/
    Linkedin
    Linkedin
    https://in.linkedin.com/company/scynexis
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Cosmoprof

    Cosmoprof

    Not Confirmed

    envelop Contact Supplier

    Cosmoprof

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    SCYNEXIS Gets FDA (QIDP) & Fast Track Designations For SCY-247
    SCYNEXIS Gets FDA (QIDP) & Fast Track Designations For SCY-247

    21 Jan 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/01/21/3222722/0/en/SCYNEXIS-Receives-FDA-Qualified-Infectious-Disease-Product-QIDP-and-Fast-Track-Designations-for-SCY-247.html

    GLOBENEWSWIRE
    21 Jan 2026
    Share Share
    Scynexis Transfers Brexafemme NDA to Gsk
    Scynexis Transfers Brexafemme NDA to Gsk

    19 Nov 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/11/19/3190785/0/en/SCYNEXIS-Completes-Transfer-of-BREXAFEMME-New-Drug-Application-to-GSK.html

    GLOBENEWSWIRE
    19 Nov 2025
    Share Share
    Scynexis Gets Federal Funding for New Fungerp Therapeutics
    Scynexis Gets Federal Funding for New Fungerp Therapeutics

    17 Nov 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/11/17/3189320/0/en/Scynexis-Announces-Federal-Funding-of-Collaboration-Between-Hackensack-Meridian-CDI-and-Johns-Hopkins-Researchers-to-Develop-New-Therapeutics-Including-Novel-Fungerps-for-Resistant.html

    GLOBENEWSWIRE
    17 Nov 2025
    Share Share
    SCYNEXIS Reveals Q3 2025 Financials & Corporate Update
    SCYNEXIS Reveals Q3 2025 Financials & Corporate Update

    05 Nov 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/11/05/3182006/0/en/SCYNEXIS-Reports-Third-Quarter-2025-Financial-Results-and-Provides-Corporate-Update.html

    GLOBENEWSWIRE
    05 Nov 2025
    Share Share
    Scynexis Secures $22M Payout From GSK After Trial Dispute
    Scynexis Secures $22M Payout From GSK After Trial Dispute

    15 Oct 2025

    // FIERCE PHARMA

    https://www.fiercepharma.com/pharma/gsk-makes-nice-antifungal-partner-scynexis-through-22m-payout-resolve-trial-dispute

    FIERCE PHARMA
    15 Oct 2025
    Share Share
    SCYNEXIS Reports Positive Ph 1 Data for SCY-247 Fungerp
    SCYNEXIS Reports Positive Ph 1 Data for SCY-247 Fungerp

    30 Sep 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/09/30/3158537/0/en/SCYNEXIS-Announces-Positive-Results-from-a-Phase-1-Single-Ascending-Dose-and-Multiple-Ascending-Dose-Study-of-its-Second-Generation-Fungerp-SCY-247.html

    GLOBENEWSWIRE
    30 Sep 2025
    Share Share

    REF. STANDARDS & IMPURITIES

    Upload your portfolio for free, ask us

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search